Levels and Distribution of Pollutants in the Waters of an Aquatic Ecosystem in Northern Mexico

The availability of good quality water resources is essential to ensure healthy crops and livestock. The objective of this study was to evaluate the level of pollution in Bustillos Lagoon in northern Mexico. Physical-chemical parameters like sodium, chloride, sulfate, electrical conductivity, nitrates, and the pesticide dichlorodiphenyltrichloroethane (DDT) were analyzed to determine the water quality available in the lagoon. Although DDT has been banned in several countries, it is still used for agricultural purposes in Mexico and its presence in this area had not been analyzed previously. Bustillos Lagoon was divided into three zones for the evaluation: (1) industrial; (2) communal lands; and (3) agricultural. The highest concentrations of sodium (2360 mg/L) and SAR (41 meq/L) reported in the industrial zone are values exceeding the United Nations Food and Agricultural Organization (FAO) irrigation water quality guidelines. DDT and its metabolites were detected in all of the 21 sites analyzed, in the agricultural zone ∑DDTs = 2804 ng/mL, this level is much higher than those reported for other water bodies in Mexico and around the world where DDT has been used heavily. The water in the communal zone is the least contaminated, but can only be recommended for irrigation of plants with high stress tolerance and not for crops

Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34-0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97-2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13-4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications. © 2006 Gomez-Reino and Loreto Carmona; licensee BioMed Central Ltd